Recursion Pharmaceuticals
RXRX
332 hedge funds and large institutions have $1.57B invested in Recursion Pharmaceuticals in 2025 Q2 according to their latest regulatory filings, with 56 funds opening new positions, 112 increasing their positions, 90 reducing their positions, and 59 closing their positions.
36% more call options, than puts
Call options by funds: $55.7M | Put options by funds: $41M
24% more repeat investments, than reductions
Existing positions increased: 112 | Existing positions reduced: 90
0% more funds holding in top 10
Funds holding in top 10: 9 → 9 (0)
0.24% less ownership
Funds ownership: 77.87% → 77.63% (-0.24%)
4% less capital invested
Capital invested by funds: $1.63B → $1.57B (-$57.8M)
5% less first-time investments, than exits
New positions opened: 56 | Existing positions closed: 59
1% less funds holding
Funds holding: 336 → 332 (-4)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$23.9M |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
+$18.6M |
| 3 |
Geode Capital Management
Boston,
Massachusetts
|
+$6.55M |
| 4 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$5.68M |
| 5 |
First Trust Advisors
Wheaton,
Illinois
|
+$4.17M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
State Street
Boston,
Massachusetts
|
-$9.36M |
| 2 |
AIM
ARK Investment Management
St. Petersburg,
Florida
|
-$8.97M |
| 3 |
UBS AM
Chicago,
Illinois
|
-$8.81M |
| 4 |
Dimensional Fund Advisors
Austin,
Texas
|
-$8.27M |
| 5 |
LCM
Laurion Capital Management
New York
|
-$8.19M |
RXRX Hedge Fund Activity: Q2 2025 in Review
332 of the 7,595 institutional investors tracked by Wall St. Rank reported a position in Recursion Pharmaceuticals (RXRX) for Q2 2025, worth a combined $1.57B — down 3.5% from $1.63B a quarter earlier.
Sellers outnumbered buyers: 59 funds closed out of RXRX and 56 opened new positions — a net loss of 3 holders — while 90 trimmed existing stakes and 112 added.
The largest buyer was BlackRock, adding an estimated $23.9M. The largest seller was State Street, cutting an estimated $9.36M.
- 332 institutional investors held Recursion Pharmaceuticals (RXRX) as of Q2 2025, down from 336 in Q1 2025.
- Funds reported $1.57B of Recursion Pharmaceuticals stock for Q2 2025, down 3.5% quarter-over-quarter.
- 56 funds opened new Recursion Pharmaceuticals positions in Q2 2025 and 59 closed out, a net change of -3 holders.
- The largest Recursion Pharmaceuticals buyer in Q2 2025 was BlackRock, an estimated $23.9M added.
- The largest Recursion Pharmaceuticals seller in Q2 2025 was State Street, an estimated $9.36M sold.
Based on aggregated 13F filings for Q2 2025.